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Precis 88 
 89 
Menopausal estrogen-only therapy use is significantly associated with increased risk of serous 90 
and endometrioid ovarian carcinomas, especially among current, long-term users.  91 
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Abstract 92 
Objective: To describe the association between postmenopausal estrogen-only therapy use and 93 
risk of ovarian carcinoma, specifically with regard to disease histotype and duration and timing 94 
of use. 95 
 96 
Methods: We conducted a pooled analysis of 906 women with ovarian carcinoma and 1,220 97 
controls; all 2,126 women included reported having had a hysterectomy. Ten population-based 98 
case-control studies participating in the Ovarian Cancer Association Consortium (OCAC), an 99 
international consortium whose goal is to combine data from many studies with similar methods 100 
so reliable assessments of risk factors can be determined, were included. Self-reported 101 
questionnaire data from each study were harmonized and conditional logistic regression was 102 
used to examine estrogen therapy’s histotype-specific and duration and recency of use 103 
associations.  104 
 105 
Results: 43.5% of the controls reported previous use of estrogen therapy. Compared to them, 106 
current-or-recent estrogen therapy use was associated with an increased risk for the serous 107 
(51.4%, OR=1.63, 95% CI 1.27-2.09) and endometrioid (48.6%, OR=2.00, 95% CI 1.17-3.41). 108 
In addition, statistically significant trends in risk according to duration of use were seen among 109 
current-or-recent postmenopausal estrogen therapy users for both ovarian carcinoma histotypes 110 
(ptrend<0.001
 for serous and endometrioid). Compared to controls, current-or-recent users for ten 111 
years or more had increased risks of serous ovarian carcinoma (36.8%, OR=1.73, 95% CI 1.26-112 
2.38) and endometrioid ovarian carcinoma (34.9%, OR=4.03, 95% CI 1.91-8.49). 113 
 114 
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Conclusions: We found evidence of an increased risk of serous and endometriod ovarian 115 
carcinoma associated with postmenopausal estrogen therapy use, particularly of long duration. 116 
These findings emphasize that risk may be associated with extended estrogen therapy use. 117 
  118 
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Introduction 119 
 Menopausal hormone therapy (HT) containing estrogens is used to relieve climacteric 120 
symptoms and prevent osteoporosis among postmenopausal women. Prior to the results of the 121 
Women’s Health Initiative (WHI) in 2002,1 approximately 13 million women in the United 122 
States used HT, and while this number declined after the WHI, there are still approximately 5 123 
million HT users.2  124 
 A comprehensive meta-analysis by Pearce et al, which included 14 population-based 125 
studies of women ages 18 to 79, showed that use of estrogen-only therapy (ET) was associated 126 
with increased risk of ovarian carcinoma (relative risk per 5 years of use=1.22).3 Recent studies 127 
since then have shown similar results2,4-6 , but important aspects remain unclear including 128 
whether differences exist by disease histotype or by duration and timing of use. The recent 129 
pooled analysis by the Collaborative Group on Epidemiological Studies on Ovarian Cancer 130 
(Collaborative Group)2 did report histotype-specific findings for serous and endometrioid 131 
cancers, but not for mucinous and clear cell cancers. They also found little trend in association 132 
with duration of use, contrary to the results of several studies.3,4,6-9  Notably, the Collaborative 133 
Group’s analysis included the majority of studies in Pearce et al’s meta-analysis in which a  134 
duration association was found. Clarifying these features could have important implications 135 
clinically and for risk stratification purposes. 136 
Estrogen-only therapy is one of the most commonly used HT types, hence a more 137 
complete characterization of the ET-ovarian carcinoma association is warranted. We have 138 
undertaken a pooled analysis of data from the Ovarian Cancer Association Consortium (OCAC) 139 
to assess ET’s histotype-specific, duration and recency of use associations with risk of ovarian 140 
carcinoma.  141 
8 
 
Materials and Methods 142 
 The OCAC is an international multidisciplinary consortium founded in 2005 143 
(http://apps.ccge.medschl.cam.ac.uk/consortia/ocac/index.html). Since many groups worldwide 144 
are conducting studies to identify risk factors and genetic variation associated with ovarian 145 
carcinoma risk, the goal of the OCAC is to provide a forum in which data from many individual 146 
studies with similar methods can be combined so reliable assessments of the risks associated 147 
with these factors can be determined. Data were sent by each study investigator to the 148 
consortium data coordinating center at Duke University, which cleaned and harmonized these 149 
data.  150 
For the pooled analysis presented here, 10 population-based case-control studies that 151 
were individually conducted and contributed data to the OCAC were included, with seven 152 
conducted in the United States and three in Europe. Details regarding each study have been 153 
published previously,10-20 but their main characteristics as well as any overlap with the 154 
Collaborative Group’s pooled analysis are presented in Table 1. Cases were women with initial 155 
diagnoses of primary  ovarian carcinoma (women with primary fallopian tube and peritoneal 156 
tumors were excluded). Eligible tumor types included serous, mucinous, endometrioid, and clear 157 
cell ovarian carcinomas as well as other epithelial tumor types that were not classified as one of 158 
these four main ovarian carcinoma histotypes including mixed cell and Brenner tumors; 159 
borderline-malignant tumors were excluded. Controls were women with ovaries (a single ovary 160 
was acceptable), who had not been diagnosed with ovarian carcinoma at the time of interview. 161 
Reference dates for the women in the studies were usually the dates of diagnosis for the cases 162 
and the dates of interview for the controls. The data used in this analysis considered events 163 
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occurring only prior to the reference dates. All studies included in this analysis had approval 164 
from ethics committees and written informed consent was obtained from all study participants. 165 
There was a total of 8,095 ovarian carcinoma patients and 13,434 controls across the ten 166 
OCAC studies. However, only women who reported having had a simple hysterectomy (without 167 
bilateral oophorectomy) were included in our analysis since estrogen-only therapy use is very 168 
infrequent among women with intact uteri as it is a confirmed risk factor for endometrial 169 
cancer,21,22 leaving us with 1,432 cases and 1,995 controls. Additional exclusions included 170 
women who were less than 50 years of age at reference date (n=387), had a prior primary cancer 171 
diagnosis (excluding non-melanoma skin cancer) (n=399), or were missing or had unknown HT 172 
information (n=141). We also excluded women who had used HT in an estrogen-progestin 173 
combined form (n=246) for simplicity of presentation and since its use is likely to skew the 174 
primary effect of estrogen-only therapy. Only women classified as non-Hispanic white, Hispanic 175 
white, or black were considered, hence our final subject set consisted of 2,126 women who had 176 
undergone hysterectomy, with 906 ovarian carcinoma cases and 1,220 controls (Figure 1).  177 
 Information regarding HT use in all forms as well as potential confounding variables 178 
selected a priori, including age, race-ethnicity, education, oral contraceptive (OC) use, parity, 179 
endometriosis, tubal ligation, age at menarche, and body mass index (typically one year before 180 
the reference date), was reported by means of self-completed questionnaires or in-person or 181 
phone interviews; we did not have information on previous salpingectomy or BRCA status at the 182 
time of this analysis. The questions used to ascertain HT use and, more specifically, estrogen-183 
only therapy use are presented in Appendix 1, available online at http://links.lww.com/xxx. 184 
 Age at menopause among women who have had a simple hysterectomy cannot be 185 
determined since the women are no longer menstruating but may still have functioning ovaries. 186 
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Hence, in our primary analysis here, we have only considered estrogen-only therapy use after age 187 
50 given that 50 is the approximate average age at menopause for women in these populations.23  188 
The majority of estrogen-only therapy use before age 50 is thus likely to be use when the women 189 
were still having regular ovulatory cycles. Given that menopause plays a central role in ovarian 190 
carcinoma etiology, it is possible that the added estrogen exposure during the period when 191 
endogenous levels of estrogen are naturally high (i.e., before menopause) is less important than 192 
exposure at older ages, the majority of which will be in the postmenopausal period.24  Hence, for 193 
the analysis presented here, we have defined estrogen-only therapy use as use after age 50, with 194 
women who only used estrogen-only therapy before age 50 included in the baseline ‘never’ users 195 
group. We also conducted sensitivity analyses to see if the results were affected if true ‘never’ 196 
users were used as the baseline comparison group and if estrogen-only therapy use was 197 
considered regardless of age at use. 198 
A common approach to dealing with the problem of an unknown age at menopause for 199 
women who had a hysterectomy is to use their age at simple hysterectomy as their age at 200 
menopause. Hence, we conducted a sensitivity analysis to assess the association between 201 
estrogen-only therapy use and ovarian carcinoma risk using such an approach. We also 202 
conducted sensitivity analyses using ages 48 and 52 instead of 50 as the age at menopause. 203 
 Estrogen-only therapy use was categorized in terms of its recency and its duration of use 204 
(in years). Current use was defined as having last used estrogen-only therapy within the past 205 
year, recent use as within the last one to four years, and past use as five or more years before the 206 
reference date. Because current and recent estrogen-only therapy users showed similar effects, 207 
they were combined in the analyses presented here. Duration of estrogen-only therapy use was 208 
summed over all episodes of use and the total categorized into the following groups: ‘never’ 209 
11 
 
(including <1 year), 1 to <5 years, 5 to <10 years, and 10 or more years of use. Women who used 210 
estrogen-only therapy for less than one year were included in the baseline ‘never’ users group as 211 
the recall of such short-term use may be greater in cases than controls. All data were cleaned and 212 
checked for internal consistency and clarifications were requested from the study investigators 213 
when needed. 214 
 Study, age, race-ethnicity, education, and OC use were included in all statistical models.  215 
We conditioned on study, age in five-year groups (50-54, 55-59, 60-64, 65-69, 70-74, 75+; finer 216 
stratification after age 75 was not warranted due to small numbers), race-ethnicity (non-Hispanic 217 
white, Hispanic white, and black), and education (less than high school, high school, some 218 
college, and college graduate or higher) and we adjusted for OC use in categories as ordinal 219 
variables ( ‘never’ (including <1 year), 1 to <2 years, 2 to <5 years, 5 to <10 years, and 10 or 220 
more years for OC use). Tubal ligation, endometriosis, parity, body mass index, and age at 221 
menarche were also considered, but their inclusion did not change the beta coefficients for the 222 
association between ET use and ovarian carcinoma (including overall, serous, or endometrioid) 223 
by more than 10% so the results given below are only adjusted for OC use. Overall, cases were 224 
missing 1.7% and 1.1% and controls 1.4% and 0.7% for OC use and education, respectively; 225 
missing categories were created for these women so their data could be used in the analysis. 226 
 Conditional logistic regression was used to calculate odds ratios (ORs) and their 95% 227 
confidence intervals (CIs) for the association between estrogen-only therapy use and risk of 228 
ovarian carcinoma. This was done for all ovarian carcinoma cases combined and for its four 229 
main histotypes. Similar analytic approaches were applied when assessing the effects of recency 230 
and duration of use. All p-values reported are two-sided. All analyses were performed using SAS 231 
9.4. 232 
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Results 233 
 Data from 906 women with ovarian carcinoma (567 serous, 113 endometrioid, 49 234 
mucinous, 42 clear cell, 135 epithelial but not specified as one of the four main histotypes) and 235 
1,220 controls, all of whom had a simple hysterectomy, were included in our analysis. Of these 236 
women, 460 cases (50.8%) and 531 controls (43.5%) reported ever having used estrogen-only 237 
therapy after age 50. Compared with the women in the control group, wmen who had used 238 
estrogen-only therapy after age 50 had a 30% increased risk of ovarian carcinoma as shown in 239 
Table 2 (50.8%, OR=1.30, 95% CI 1.06-1.59). Most of this risk elevation was observed among 240 
long-term users of estrogen-only therapy for 10 years or more (both current or recent and past 241 
users).  242 
 In addition, the estrogen-only therapy-ovarian carcinoma association appeared to show 243 
distinct histotype-specific associations as presented in Table 3 (serous and endometrioid) and 244 
Appendix 2, available online at http://links.lww.com/xxx (mucinous and clear cell). Compared 245 
with the women in the control group, current or recent estrogen-only therapy use was statistically 246 
significantly associated with an increased risk of both serous (51.4%, OR=1.63, 95% CI 1.27-247 
2.09) and endometrioid (48.6%, OR=2.00, 95% CI 1.17-3.41) histotypes, but not mucinous 248 
(31.3%, OR=0.93, 95% CI 0.43-2.00) and clear cell (39.0%, OR=0.87, 95% CI 0.40-1.88) 249 
histotypes, although the confidence limits for the mucinous and clear cell effect estimates were 250 
wide due to small numbers of cases. When we looked at high-grade (moderately differentiated, 251 
poorly differentiated, undifferentiated) and low-grade (well differentiated) serous ovarian 252 
carcinomas separately, we found increased risks for both and hence the results for all serous 253 
cases combined are given. 254 
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Trends in association with duration of estrogen-only therapy use were observed for the 255 
serous (ptrend<0.001) and endometrioid (ptrend<0.001) histotypes among current or recent 256 
estrogen-only therapy users. Across all histotypes and duration and timing categories, estrogen-257 
only therapy appeared to have the strongest association with risk of endometrioid ovarian 258 
carcinoma; compared with the women in the control group, current or recent, long-term users of 259 
estrogen-only therapy for 10 years or more had over a four-fold increased risk (34.9%, OR=4.03, 260 
95% CI 1.91-8.49). Current or recent, long-term users also had nearly a two-fold increased risk 261 
of serous ovarian carcinoma (36.8%, OR=1.73, 95% CI 1.26-2.38) when compared with women 262 
in the control group.  In addition, there appeared to be elevated risks of 1.49, 2.07, and 1.82 for 263 
overall, serous, and endometrioid ovarian carcinoma, respectively, when we compared past, 264 
long-term ET users to our baseline ‘never’ user group (Tables 2 and 3). 265 
Because we assumed that all women in our analysis had an age at menopause of 50, we 266 
conducted a sensitivity analysis in which each woman’s age at simple hysterectomy was used as 267 
her age at menopause, with the duration and timing of use variables re-categorized as such. The 268 
results by duration, timing of ET use, and histotype slightly attenuated with ORs of 1.46, 1.64, 269 
and 3.72 among current-or-recent ET users of 10 years or more for ovarian carcinoma overall 270 
and the serous and endometrioid histotypes, respectively (Appendix 3, available online at 271 
http://links.lww.com/xxx). Sensitivity analyses that used a true ‘never’ user baseline group and 272 
redefined ET use regardless of age at menopause or with ages 48 and 52 as the age at menopause 273 
did not affect the overall findings (data not shown). 274 
 275 
Discussion 276 
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 Most population-based case-control studies and cohort studies have shown that estrogen-277 
only therapy use is associated with an increased risk of ovarian carcinoma and considering our 278 
findings together with those recently published by the Collaborative Group,2 it seems clear that 279 
estrogen-only therapy is associated with risk for the serous and endometrioid histotypes of the 280 
disease. We found greater increased risk for those who used estrogen-only therapy for 10 years 281 
or more, including those who last used it more than 5 years in the past, whereas the Collaborative 282 
Group2 did not. This was surprising given that the individual studies that contributed the most 283 
statistical information to their analysis (the Million Women Study (MWS)7 and the Danish Sex 284 
Hormone Register Study (DaHoRS)4) reported duration associations with estrogen-only therapy 285 
use in their primary publications.  The meta-analysis from Pearce el al3 showed evidence of an 286 
estrogen-only therapy duration-ovarian carcinoma risk association as well.  287 
From a biological standpoint, an elevated risk of endometrioid ovarian carcinoma with 288 
estrogen-only therapy use is not surprising given that the cells of origin are histologically similar 289 
to endometrial tissue,25 and estrogen-only therapy use is a confirmed risk factor for endometrial 290 
cancer.21 Danforth et al26 had suggested that estrogen-only therapy may act through similar 291 
biologic mechanisms in the development of endometrioid tumors as it does in endometrial 292 
cancer. Given the increased risk we see for endometrioid ovarian carcinoma and the well-293 
established association between endometriosis and the endometrioid and clear cell histotypes,27 294 
we assessed the estrogen-only therapy risk association according to previous history of 295 
endometriosis or not, but did not see any heterogeneity in risk (data not shown).  296 
 Although the exact mechanism by which estrogen-only therapy might affect serous and 297 
endometrioid ovarian carcinoma risk remains unknown, estrogens have long been implicated as 298 
etiologic factors.28 Ovarian carcinogenesis may be a result of the direct effects of unopposed 299 
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estrogen and an estrogen-rich environment, which would potentially be enhanced by estrogen-300 
only therapy use. The use of estrogen-only therapy may also directly stimulate the growth of 301 
premalignant or early malignant cells with long-term use increasing the risk of transformation or 302 
proliferation.29 In addition, the fallopian tube fimbriae , a proposed cell of origin for high-grade 303 
serous carcinoma, have been shown to proliferate at times when estrogenic influences are greater 304 
during the menstrual cycle,30,31 and this increased activity results in greater cell proliferation 305 
which may enhance the risk of mutations and malignant transformation. Estradiol has also been 306 
shown to increase ovarian carcinoma cell proliferation in vitro32 and influence the growth of 307 
ovarian tumors in a transplanted mouse model.33 Therefore, while several hypotheses have been 308 
put forth to explain ovarian carcinoma etiology, unopposed estrogen appear to play an important 309 
role.  310 
 Limitations of our analysis include the self-reported nature of our data. Because case-311 
control studies inquire about previous exposures when subjects are already aware of their disease 312 
status, recall bias is possible as cases may be more likely to search for explanations for their 313 
disease and assign greater significance to past events than controls. However, studies have 314 
shown high agreement between self-reported estrogen use and prescription data.34 In addition, 315 
case patients have not been shown to preferentially report HT use more than controls.35 We 316 
considered estrogen-only therapy use only after age 50 to be relevant in an attempt to mainly 317 
consider only use after ovarian function had ceased. Sensitivity analysis showed little effect 318 
when changing this to age 48 or 52, the latter which will only include use that is almost all in the 319 
postmenopausal period.  320 
 A potential concern with case-control studies such as those included in our analysis is 321 
that some ineligible women (those who had a bilateral oophorectomy) could have been recruited 322 
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as controls even though they would not be at risk of developing ovarian carcinoma. However, 323 
oophorectomy results in a loss of estrogen production, which may make such women more likely 324 
to use estrogen-only therapy, thus potentially biasing our findings towards the null.  If this type 325 
of bias is present, any association between estrogen-only therapy use and risk of ovarian 326 
carcinoma would be underestimated.  327 
Our analysis offers evidence of an increased risk of ovarian carcinoma with ET use after 328 
the age of 50. This is especially true for risk of serous and endometrioid tumors for long 329 
durations of use, shedding light on the distinct histotype-specific etiologies. Although ET use has 330 
declined since the WHI, a significant number of women continue to use it today. Physicians and 331 
patients should be aware of the risk of ovarian carcinoma associated with its long-term use.  332 
333 
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Table 1. Description of studies included in analysis 424 
Study Name 
Time 
Period 
Location 
Case 
Ascertainment 
Control 
Ascertainment 
Controls 
(mean/IQR 
for age) 
Cases 
(mean/IQR 
for age) 
Serous 
Muci- 
ous 
Endom-
etrioid 
Clear 
cell 
Connecticut Ovary Study 
(CON) 19 
2002-
2009 
USA; CT 
Cancer registry or hospital 
records 
Random digit dialing, 
Health Care Financing 
Administration records 
49 
(60.9/13) 
54 
(62.2/12) 
 
28 
 
 
4 
 
 
12 
 
 
4 
 
Disease of the Ovary 
Study and their Evaluation 
(DOV) 18 
2002-
2009 
USA; WA Cancer registry Random digit dialing 
224 
(66.8/12) 
159 
(62.7/8) 
108 3 15 3 
German Ovarian Cancer 
Study (GER) 10, * 
1992-
1998 
Germany 
Admissions to all 
hospitals serving the study 
regions 
Population registries 
89 
(60.9/11) 
34 
(61.5/12) 
 
17 
 
 
2 
 
 
2 
 
 
1 
 
Hawaii Ovarian Cancer 
Study (HAW) 12 
1994-
2007 
USA; HI Cancer registry 
Department of Health 
Annual Survey, Health 
Care Financing 
Administration records 
40 
(67.3/16) 
32 
(66.1/17) 
 
18 
 
 
1 
 
 
5 
 
 
2 
 
Hormones and Ovarian 
Cancer Prediction (HOP) 
13, * 
2003-
2008 
USA; western 
PA, northeast 
OH, western 
NY 
Cancer registries, 
pathology databases, 
physicians’ offices 
Random digit dialing 
201 
(65.5/16) 
100 
(66.6/15.6) 
 
57 
 
 
5 
 
 
17 
 
 
4 
 
Malignant Ovarian Cancer 
Study (MAL) 20 
1994-
1999 
Denmark 
Cancer registry, 
gynecological departments 
Random digit dialing 
84 
(62.6/13) 
47 
(61.7/11) 
25 4 8 5 
North Carolina Ovarian 
Cancer Study (NCO) 14 
1999-
2008 
USA; NC Cancer registry Random digit dialing 
126 
(62.7/11) 
153 
(62.9/10) 
 
94 
 
 
5 
 
 
16 
 
 
11 
 
New England Case-
Control Study of Ovarian 
Cancer (NEC) 16 
1999-
2008 
USA; NH and 
eastern MA 
Cancer registries, hospital 
tumor boards 
Random digit dialing, 
town books, drivers’ 
license lists 
67 
(63.2/11) 
50 
(63.4/12) 
 
38 
 
 
1 
 
 
6 
 
 
1 
 
United Kingdom Ovarian 
Cancer Population Study 
(UKO) 11 
2006-
2007 
United 
Kingdom 
Gynecological Oncology 
NHS centers 
Women in the general 
population participating 
in the United Kingdom 
Collaborative Trial of 
Ovarian Cancer 
Screening (UKCTOCS) 
116 
(64.0/9) 
56 
(67.0/12) 
 
30 
 
 
7 
 
 
12 
 
 
4 
 
University of Southern 
California. Study of 
Lifestyle and Women’s 
Health (USC) 15,17, * 
1993-
2005 
USA; Los 
Angeles, CA 
Cancer registry Neighborhood controls 
224 
(62.9/12.5) 
217 
(64.7/12) 
152 17 20 7 
    Total: 1220 906† 567† 49† 113† 42† 
Note: All studies used in-person interviews except GER, which used self-completed questionnaires. MAL used either in-person or phone interviews. 425 
* Some of the study’s data were included in the Collaborative Group’s2 analysis. 426 
† Sum of numbers do not equal total number of cases because some cases were not classified as one of the four main histotypes considered. 427 
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Table 2. Association between estrogen-only therapy use over age 50 and risk of ovarian carcinoma overall 
Categories of ET 
Use 
Number 
of 
controls 
Number 
of cases 
Median 
duration 
(years) 
OR* 95% CI p-value 
Never used 689 446 -- 1.00 -- -- 
Ever 531 460 9.20 1.30 1.06 – 1.59 0.013 
   1 to<5 years 149 92 2.70 1.00 0.72 – 1.39 0.99 
   5 to<10 years 155 135 7.45 1.27 0.93 – 1.72 0.13 
   10+ years 227 233 15.12 1.54 1.18 – 2.01 0.002 
     p-trend: 0.001 
       
   Current-or- 
   recent users† 
432 392 10.00 1.35 1.09 – 1.67 0.006 
      1 to <5 years 103 67 3.00 1.00 0.68 – 1.48 0.99 
      5 to <10 years 120 112 7.20 1.35 0.96 – 1.90 0.087 
      10+ years 209 213 15.20 1.53 1.17 – 2.02 0.002 
     p-trend: <0.001 
       
   Past users 99 68 6.20 1.07 0.74 – 1.56 0.72 
      1 to <5 years 46 25 2.20 1.01 0.59 – 1.74 0.97 
      5 to <10 years 35 23 8.20 1.03 0.57 – 1.86 0.93 
      10+ years 18 20 13.28 1.49 0.71 – 3.13 0.29 
     p-trend: 0.95 
Note: OR=odds ratio, CI = confidence interval. 
* Adjusted for oral contraceptive use (never (including <1), 1 to <2, 2 to <5, 5 to <10, 10+ years) and conditioned on 
age (50-54, 55-59, 60-64, 65-69, 70-74, 75+), education (less than high school, high school, some college, college 
graduate or higher), race-ethnicity (non-Hispanic white, Hispanic white, black), and study. 
† Current-or-recent users included those who used estrogen-only therapy within the last five years prior to their 
reference age. 
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Table 3. Association between estrogen-only therapy use after age 50 and risk of serous and endometrioid ovarian carcinoma 
  SEROUS (N=567) ENDOMETRIOID (N=113) 
Categories of ET 
Use 
Number 
of 
controls 
Number 
of cases 
OR* 95% CI p-value 
Number 
of cases 
OR* 95% CI p-value 
Never used 689 252 1.00 -- -- 54 1.00 -- -- 
Ever 531 315 1.57 1.23 – 2.00 <0.001 59 1.82 1.10 – 3.03 0.021 
   1 to <5 years 149 62 1.26 0.86 – 1.83 0.24 10 0.98 0.45 – 2.15 0.97 
   5 to <10 years 155 92 1.58 1.11 – 2.25 0.012 17 1.64 0.78 – 3.47 0.19 
   10+ years 227 161 1.79 1.31 – 2.43 <0.001 32 3.58 1.74 – 7.36 <0.001 
    p-trend: <0.001   p-trend: <0.001 
          
   Current-or- 
   recent users† 
432 267 1.63 1.27 – 2.09 <0.001 51 2.00 1.17 – 3.41 0.011 
      1 to <5 years 103 46 1.37 0.88 – 2.14 0.16 7 0.88 0.35 – 2.19 0.78 
      5 to <10 years 120 74 1.69 1.14 – 2.52 0.010 15 1.72 0.76 – 3.87 0.19 
      10+ years 209 147 1.73 1.26 – 2.38 <0.001 29 4.03 1.91 – 8.49 <0.001 
         p-trend: <0.001   p-trend: <0.001 
          
   Past users 99 48 1.28 0.83 – 1.96 0.27 8 1.20 0.48 – 3.01 0.69 
      1 to <5 years 46 16 1.05 0.55 – 2.01 0.89 3 1.35 0.37 – 4.94 0.66 
      5 to <10 years 35 18 1.26 0.65 – 2.43 0.50 2 1.46 0.25 – 8.66 0.68 
      10+ years 18 14 2.07 0.89 – 4.79 0.091 3 1.82 0.40 – 8.19 0.44 
    p-trend: 0.46   p-trend: 0.35 
Note: OR=odds ratio, CI=confidence interval 
* Adjusted for oral contraceptive use (never (including <1), 1 to <2, 2 to <5, 5 to <10, 10+ years) and conditioned on age (50-54, 55-59, 60-64, 65-69, 70-74, 
75+), education (less than high school, high school, some college, college graduate or higher), race-ethnicity (non-Hispanic white, Hispanic white, black), and 
study. 
† Current or recent users included those who used estrogen-only therapy within the last five years prior to their reference age. 
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Figure 1. Flowchart of analysis exclusions 
 
 
